Floatz logo

Dual-Target Antigen-Selected Car-Nk

Melanoma (Skin Cancer)

Essen BiotechCell therapyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

151 Active assets in the Melanoma (Skin Cancer) cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
DACARBAZINE
Linnaeus Therapeutics, Inc.
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB
CIS-DIAMMINEDICHLOROPLATINUM II
MIPO Clinic
Phase 3BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB

View all 50 →

Same molecule, other indications

Dual-Target Antigen-Selected Car-Nk is also rated in:

prostate cancerDormant
CCC
Indicative ·
48 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
47 / 100
View asset →
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →